Lecanemab, a new drug, has been shown to slow the decline of Alzheimer's disease in a clinical trial. However, it must be given early in the disease and there are risks associated with the drug. Scientists caution that amyloid is only one part of the complex picture of Alzheimer's disease and the emergence of drugs that alter the course of the disease raises questions about whether the health service is ready to use them. The article also includes news about medical research, health, and dementia, as well as other current events.